Research Analysts Offer Predictions for Protalix BioTherapeutics, Inc.’s FY2024 Earnings (NYSE:PLX)

Protalix BioTherapeutics, Inc. (NYSE:PLX) – Investment analysts at Zacks Small Cap dropped their FY2024 earnings per share estimates for Protalix BioTherapeutics in a research report issued to clients and investors on Wednesday, May 15th. Zacks Small Cap analyst J. Vandermosten now forecasts that the company will post earnings per share of $0.12 for the year, down from their prior forecast of $0.21. The consensus estimate for Protalix BioTherapeutics’ current full-year earnings is $0.12 per share. Zacks Small Cap also issued estimates for Protalix BioTherapeutics’ Q4 2024 earnings at $0.10 EPS, FY2025 earnings at $0.63 EPS and FY2026 earnings at $1.13 EPS.

Protalix BioTherapeutics (NYSE:PLX) last released its earnings results on Friday, May 10th. The company reported ($0.06) EPS for the quarter. Protalix BioTherapeutics had a return on equity of 19.48% and a net margin of 11.48%. The firm had revenue of $3.75 million during the quarter.

Separately, StockNews.com lowered Protalix BioTherapeutics from a “buy” rating to a “hold” rating in a research note on Friday, March 15th.

Protalix BioTherapeutics Trading Down 2.6 %

PLX stock opened at $1.14 on Monday. The company has a market cap of $83.58 million, a price-to-earnings ratio of 28.50 and a beta of 0.90. The firm has a 50 day moving average of $1.22 and a 200-day moving average of $1.44. Protalix BioTherapeutics has a 12-month low of $1.03 and a 12-month high of $2.51.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Bank of New York Mellon Corp raised its position in shares of Protalix BioTherapeutics by 12.8% during the third quarter. Bank of New York Mellon Corp now owns 165,680 shares of the company’s stock worth $275,000 after purchasing an additional 18,760 shares during the period. SG Americas Securities LLC purchased a new stake in shares of Protalix BioTherapeutics during the 3rd quarter worth about $50,000. Barclays PLC grew its stake in shares of Protalix BioTherapeutics by 251.6% in the 3rd quarter. Barclays PLC now owns 46,511 shares of the company’s stock valued at $77,000 after buying an additional 33,281 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its holdings in Protalix BioTherapeutics by 45.0% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 167,536 shares of the company’s stock worth $278,000 after buying an additional 51,997 shares during the last quarter. Finally, Bailard Inc. acquired a new stake in Protalix BioTherapeutics in the fourth quarter valued at approximately $121,000. Institutional investors and hedge funds own 16.53% of the company’s stock.

About Protalix BioTherapeutics

Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.